TABLE A3.

Self-Rated AESI During Cycle B

Adverse Event	THC:CBD, No. (%)	Placebo, No. (%)	THC:CBD, No. (%)	Placebo, No. (%)
	Any severity		Moderate or severe
Sedation	51 (59)	13 (29)	14 (16)	2 (4)
Dizziness	6 (7)	3 (7)	0	0
Anxiety	15 (17)	2 (4)	3 (3)	0
Disorientation	42 (49)	7 (16)	11 (13)	2 (4)
Hallucinations	9 (10)	0	0	0
Palpitations	2 (2)	0	0	0
Any AESIa	64 (74)	17 (38)	21 (24)	3 (7)

NOTE. Self-rated AESI were collected during daily assessment between D-1 and D6, and included the following known cannabis-related adverse events: sedation, anxiety, disorientation, dizziness, hallucinations, and palpitations.

Abbreviations: AESI, adverse events of special interest; CBD, cannabidiol; THC, tetrahydrocannabinol.

^a Number of participants experiencing ≥1 event during cycle B.